Healthcare
•3762 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3762)
| Company | Market Cap | Price |
|---|---|---|
|
SERA
Sera Prognostics, Inc.
Ambient blood collection kits and other medical device consumables used to perform the PreTRM test, enabling easier sample collection.
|
$120.55M |
$3.11
-2.81%
|
|
RPID
Rapid Micro Biosystems, Inc.
Growth Direct is a diagnostic equipment platform for automated microbial detection used in pharmaceutical QC.
|
$120.54M |
$2.69
-2.18%
|
|
JYNT
The Joint Corp.
The Joint operates chiropractic clinics delivering hands-on care, representing a healthcare services & facilities business.
|
$120.36M |
$7.76
-1.27%
|
|
IKT
Inhibikase Therapeutics, Inc.
IKT's lead program IKT-001Pro is an oral small-molecule therapeutic prodrug, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$118.95M |
$1.65
+3.12%
|
|
PDEX
Pro-Dex, Inc.
Direct product: the company manufactures surgical instruments (autoclavable, battery-powered multi-function handpieces and shavers).
|
$117.11M |
$34.99
-2.53%
|
|
ULBI
Ultralife Corporation
Products targeted at medical use (X5 medical care products, wearable power) place Ultralife in Medical Devices & Biometrics.
|
$115.60M |
$6.91
-0.58%
|
|
XTNT
Xtant Medical Holdings, Inc.
Company designs, manufactures, and sells orthopedic surgical implants (e.g., spinal implants) and orthobiologic products.
|
$113.05M |
$0.83
+2.29%
|
|
SRZN
Surrozen, Inc.
Direct ophthalmic drug development focusing on retinal diseases using Wnt-modulating antibodies.
|
$111.83M |
$13.34
+2.14%
|
|
ATOS
Atossa Therapeutics, Inc.
Atossa is a clinical-stage biotech focused on oncology with Z-endoxifen as its lead cancer therapy candidate.
|
$111.51M |
$0.84
-2.61%
|
|
AGEN
Agenus Inc.
Agenus' core focus is oncology with immunotherapy approaches (BOT/BAL) in MSS CRC, supporting Biotech - Oncology.
|
$108.84M |
$3.75
-5.54%
|
|
TVGN
Tevogen Bio Holdings Inc.
ExacTcell off-the-shelf T cell therapies and the TVGN 489 program position Tevogen as a cell therapy biotech focused on oncology and infectious disease.
|
$108.15M |
$0.56
-4.20%
|
|
NCSM
NCS Multistage Holdings, Inc.
Tracer diagnostics capabilities and studies are a key service offering for reservoir and well performance analysis.
|
$107.71M |
$40.20
-5.17%
|
|
CLNN
Clene Inc.
Clene's proprietary clean-surfaced nanotechnology platform operates as a drug delivery platform for CNM-Au8.
|
$107.61M |
$11.29
-5.72%
|
|
TIL
Instil Bio, Inc.
Instil Bio's lead candidate AXN-2510/IMM2510 is a bispecific antibody, placing the company squarely in the Bispecific Antibodies investable theme.
|
$106.93M |
$15.68
-3.83%
|
|
ICAD
iCAD, Inc.
iCAD operates in the Medical Imaging domain, providing imaging software for breast health diagnostics.
|
$105.91M |
$3.87
|
|
HLVX
HilleVax, Inc.
Direct vaccine development activity with norovirus vaccine candidates (HIL-216.00) and existing vaccine focus.
|
$104.79M |
$2.09
|
|
ANEB
Anebulo Pharmaceuticals, Inc.
Anebulo's lead candidate selonabant is a small molecule therapeutic (initially oral) targeting cannabis-induced CNS effects; thus aligns with Oral Small Molecule Therapeutics.
|
$104.36M |
$2.55
+0.39%
|
|
ZNTL
Zentalis Pharmaceuticals, Inc.
Zentalis is a biotech company focused on oncology therapies, centered on cancer indications with their lead asset azenosertib.
|
$103.61M |
$1.31
-8.68%
|
|
PLRX
Pliant Therapeutics, Inc.
Company's lead and mid-stage assets include oral small-molecule therapeutics (bexotegrast and PLN-101095) targeting integrin pathways.
|
$102.52M |
$1.60
-3.89%
|
|
NIKA
Nika Pharmaceuticals Inc.
ITV-1 HIV therapeutic concept and related immunomodulatory platform sit within Biotech - Immunology Therapeutics.
|
$102.15M |
$0.30
|
|
DCGO
DocGo Inc.
DocGo directly provides Home Health & Hospice services, including in-home/mobile healthcare delivery.
|
$102.08M |
$1.04
+1.46%
|
|
CGTX
Cognition Therapeutics, Inc.
CT1812 (zervimesine) is an orally delivered small-molecule therapeutic, the core product of the company.
|
$101.67M |
$1.57
-3.96%
|
|
IMMX
Immix Biopharma, Inc.
Directly categorizes the company’s lead product as a CAR-T cell therapy (cell therapy).
|
$101.47M |
$3.29
-9.62%
|
|
COYA
Coya Therapeutics, Inc.
COYA's autologous regulatory T cell therapy program (COYA 101) represents a direct cell therapy product line.
|
$100.35M |
$5.86
-2.33%
|
|
RCEL
AVITA Medical, Inc.
RECELL System and Cohealyx/PermeaDerm are wound care devices used for wound closure and healing.
|
$99.92M |
$3.67
-2.91%
|
|
MGNX
MacroGenics, Inc.
Company develops bispecific antibody therapies via its DART platform, including lorigerlimab.
|
$99.68M |
$1.45
-8.23%
|
|
QIPT
Quipt Home Medical Corp.
Quipt designs/markets medical devices and biometric sensing technology used in home respiratory care and diabetes monitoring (CGMs).
|
$99.11M |
$2.31
+0.65%
|
|
FONR
FONAR Corporation
Core product offering is the Upright MRI hardware, a specialized medical imaging platform.
|
$98.92M |
$14.89
-0.87%
|
|
MIST
Milestone Pharmaceuticals Inc.
Milestone's lead candidate etripamil is a cardiovascular drug developed for PSVT and AFib-RVR.
|
$98.91M |
$1.84
-0.27%
|
|
SLGL
Sol-Gel Technologies Ltd.
SGT-610 and SGT-210 target rare dermatologic diseases (Gorlin syndrome, Darier disease), aligning with the Rare Diseases investable theme.
|
$98.89M |
$33.95
-4.37%
|
|
CNTX
Context Therapeutics Inc.
The company's pipeline centers on T cell engaging bispecific antibodies (CTIM-76, CT-95, CT-202).
|
$96.88M |
$1.09
+0.93%
|
|
ORMP
Oramed Pharmaceuticals Inc.
Oramed's POD platform constitutes the core drug-delivery technology enabling oral administration of therapeutic proteins (e.g., oral insulin).
|
$96.41M |
$2.29
-3.18%
|
|
KBLB
Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories produces recombinant spider silk proteins via transgenic silkworms, a core product category defined as Recombinant Proteins & Enzymes.
|
$96.23M |
$0.09
|
|
STTK
Shattuck Labs, Inc.
SL-325 is a monoclonal antibody targeting DR3, making Monoclonal Antibody Therapeutics a direct product category.
|
$95.32M |
$1.98
-0.75%
|
Showing page 25 of 38 (3762 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
